Ongoing funding events
Our ongoing funding events are shown below.
Any research proposal involving a collaboration with one or more industrial partners (contributing either in cash or in kind) is handled by MRC as a MICA. MICA is not a scheme in itself, but a mechanism to support the establishment of an agreement between academic and industry research partners, which can be applied to the majority of MRC’s funding schemes and calls (to find out if you can apply a MICA to your proposal, please refer to your specific scheme or call). MICA facilitates collaboration as it allows partners to work out and clearly specify arrangements for relative responsibilities, governance, regulatory approvals, indemnity, intellectual property rights, reporting, and access to data and samples before a project starts. In addition, MICAs help to establish that proposed collaboration arrangements are eligible under EU State-Aid regulations for MRC funding.
Through its Long-range Research Initiative, the European Chemical Industry has tendered for research in the following areas:
• Critical review of epidemiological evidence for the potential association between endocrine active chemical and obesity, diabetes and cardiovascular disease. Award funding: €100,000 over 4-5 months.
• Contribution of dust to human exposure. Award funding: €350,000 over two years.
• Development of an alternative testing strategy for the fish early life-stage test –OECD 210. Award funding: €500,000 over three years.
• Development of an in silico model of dermal absorption. Award funding: €500,000 over three years.
• Development of an integrated approach to predict internal exposure to chemicals. Award funding: €300,000 over two years.
• Foresight study on introduction of new technologies – the case of nanotechnology. Award funding: €150,000 over one year.
• Mechanistic bioaccumulation models for ionogenic organic substances in fish. Award funding: €300,000 over two years.
• Towards more ecologically realistic assessment of chemicals in the environment. Award funding: €500,000 and €700,000 over 3-4 years.
These awards are fixed-price contracts between the Council and the awardee.
Eligibility: Applicants should provide an indication of additional partners and funding opportunities that can be leveraged as part of their proposal.
The BBSRC new pathfinder scheme enables potential follow-on funding applicants to secure small amounts of funding to carry out preliminary commercial activities.
The Brian Mercer Feasibility Awards aim to provide initial support to test the feasibility of a project and enable holders to investigate the technical and economical feasibility of commercialising an aspect of their scientific research, possibly in conjunction with a third party. These awards are designed to promote innovation and are intended to fill the funding gap between the scientific research and the exploitation of the idea through venture capital. The scheme covers the built environment, clean technology, energy and nanoscience and nanotechnology.
Funded by BBSRC and delivered by the Royal Society of Edinburgh, Enterprise Fellowships are designed to encourage the development of a new business, building on previously funded BBSRC research, around a technological idea developed by the Fellow (either individually or with others) and within which the Fellow would be expected to play a leading (though not necessarily the leading) role. This award is of particular relevance to individuals and ideas who previously received BBSRC Follow-on Funding (although not exclusively).
A year’s salary to provide time to develop a full business plan and seek investment
Access to mentors, business experts and professional advisors
Business training to help develop the required skills
Academic and research staff and postgraduates with relevant experience are eligible to apply if employed by a:
UK Higher Education Institution (HEI), or
Institutes of BBSRC
Invited applications for applied R&D projects that are close to existing Wellcome Trust interests. For example, these may build on Trust initiatives in basic science, such as genome-wide association studies, healthcare in low- and middle-income countries, or in areas like malaria, typhoid or TB.